The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2024 | Predicting OS with PFS in pancreatic cancer in the NAPOLEON-1 and -2 trials
Tsuyoshi Shirakawa, MD, PhD, Eikoh Hospital and Clinical Hematology Oncology Treatment Study Group, Fukuoka, Japan, explores whether progression-free survival (PFS) can serve as a surrogate marker for overall survival (OS) in pancreatic cancer treatments involving fluorouracil, leucovorin, irinotecan, and oxaliplatin (FFX) or gemcitabine plus nab-paclitaxel. Through an integrated analysis of the NAPOLEON-1 and NAPOLEON-2 studies (UMIN000043939), a strong correlation between PFS and OS for both 1st- and 2nd-line therapies was demonstrated. The findings suggest that PFS can reliably predict OS, aiding in treatment selection and prognostic estimation for pancreatic cancer patients. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
